BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Health > article

State watchdog starts screening Celltrion's antibody treatment for COVID-19

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : December 29, 2020, 17:24 | Updated : December 29, 2020, 17:24
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Celltrion]


SEOUL -- South Korea's drug safety watchdog began evaluating the safety and efficacy of Celltrion's antibody treatment code-named CT-P59, which has been developed as an intravenous injection for patients with mild and moderate symptoms. It would be South Korea's first treatment for COVID-19.

The Ministry of Food and Drug Safety said it would complete the screening of CT-P59 within 40 days. Celltrion has said that CT-P59 shortened the recovery time of patients with no reported side effects, while it eradicated the virus in up to five days, effectively protecting patients with mild symptoms from developing into a severe case.

Celltrion said it has submitted a formal application for CT-P59's conditional marketing authorization (CMA). For second-stage clinical trials, 327 patients with mild-to-moderate symptoms have been enrolled. The company would initiate Phase III clinical trials in more than 10 countries to obtain more comprehensive safety and efficacy results.

"We remain committed to closely working with the regulatory agencies worldwide including the U.S. FDA and the European Medicines Agency (EMA) to ensure that patients around the world have access to safe and effective treatment against COVID-19 as early as possible," Celltrion's medical and marketing division head Kim Ho-ung said in a statement on December 29.

CT-P59 has been developed through a process of extracting a neutralizing gene and recombining it into host cells that can be mass-produced. The high price of antibody drugs has been cited as a disadvantage. Although Celltrion has yet to disclose its price, it has repeatedly promised to supply it at the 'cost' level in South Korea.

Celltrion, a bio firm involved in a state project to find the treatment of COVID-19 patients, has already finished producing CT-P59 that can be used by 100,000 patients. As CT-P59 has the advantage of forming antibodies immediately after administration, medical personnel and other vulnerable people will be able to prevent infections.

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • . Celltrion revises deal with U.S. client to ship new rapid COVID-19 antigen test kit.
    Celltrion revises deal with U.S. client to ship new rapid C…
  • .  Celltrion checks antibody treatments effect of COVID-19 infection prevention    .
    Celltrion checks antibody treatment's effect of COVID-19 i…
  • .Celltrion allowed to go ahead with last-stage clinical test of COVID-19 antibody treatment.
    Celltrion allowed to go ahead with last-stage clinical test …
  • .Anti-epidemic center considers introducing rapid antigen inspection.
    Anti-epidemic center considers introducing rapid antigen ins…
  • .Celltrion leaves door open for consignment production of COVID-19 vaccines.
    Celltrion leaves door open for consignment production of COV…

Real Time Photo News

  • .Singer IU drops teaser image for upcoming full album.

    Singer IU drops teaser image for upcoming full album

  • .Cube Entertainment partners with web comics company to create online video content.

    Cube Entertainment partners with web comics company to create online video content

  • .Sci-fi film starring Song Joong-ki to be reelased on Netflix in February.

    Sci-fi film starring Song Joong-ki to be reelased on Netflix in February

  • .Actor Kim Soo-hyun to star in S. Korean remake of British TV drama series Criminal Justice.

    Actor Kim Soo-hyun to star in S. Korean remake of British TV drama series 'Criminal Justice'

  • .CJ ENM partners with NCSoft to roll out new digital content for global market.

    CJ ENM partners with NCSoft to roll out new digital content for global market

Latest News

more+

  • New negative-pressure ambulances to be used by S. Korean fire stations
  • Doosan Mobility's hydrogen drones to be used for safe voyage solutions
  • Samsung supports smart production of COVID-19 vaccine syringes
  • S. Korean hospital opens colonofiberscope center installed with AI medical software
  • S. Korea to develop technologies for efficient recycling of discarded batteries
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view